Business Overview: iRhythm Holdings, Inc. (NASDAQ: IRTC)

---

Executive Summary

iRhythm Holdings, Inc. (the parent holding company that became the successor registrant to iRhythm Technologies, Inc. on January 12, 2026) is a digital healthcare company that provides ambulatory cardiac monitoring (ACM) services built around its Zio patch monitors, proprietary deep-learning ECG analysis algorithms, and a Medicare-enrolled diagnostic-testing-facility service model.

iRhythm matters because it is the category leader it helped create: the company estimates it holds more than 70% of U.S. long-term continuous monitoring (LTCM) services and roughly 40% penetration of the core ACM market, on $747.1 million in 2025 revenue, up 26.2% year over year — a business built not around selling a device, but around selling a full monitoring-and-diagnosis service that happens to use a wearable patch.

---

1. Core Business Model & How They Work

Unlike a typical medical device company, iRhythm does not sell its Zio patches as standalone hardware — it sells a complete ambulatory cardiac monitoring service, with the patch as just the data-collection component of a workflow that also includes proprietary analysis software and Medicare-enrolled testing facilities.

[ Physician Orders Zio Monitoring ] ➡️ [ Patient Wears Zio Patch (up to 14 days) ] ➡️ [ AI-Assisted ECG Analysis (ZEUS) ] ➡️ [ Technician Validation at IDTF ] ➡️ [ Report via ZioSuite/EHR to Physician ] ➡️ [ Billing to Payor (CPT codes) ]

Key Operational Drivers

1. Service, Not Device, Revenue Model: Zio patches are bundled into the ACM service and billed under CPT codes rather than sold as hardware — roughly 83% of 2025 revenue came from third-party payors, including about 24% from Medicare, with the company expecting a continued mix shift toward commercial billing.
2. Proprietary AI-Assisted Analysis: FDA-cleared deep-learning algorithms generate preliminary ECG findings that trained technicians then validate — combining automation with clinical oversight in a workflow that is difficult for a pure hardware competitor to replicate quickly.
3. Vertically Integrated Service Delivery: iRhythm operates its own Medicare-enrolled Independent Diagnostic Testing Facilities (IDTFs) and employs its own qualified technicians, rather than simply shipping a device and leaving interpretation to the customer.
4. Direct Manufacturing Control: Devices are manufactured at a roughly 69,000-square-foot leased facility in Cypress, California, under ISO 13485:2016 certification, with capacity the company says is sufficient for at least five years, though some components (ASICs, applicator seals, sensor polymers) remain single-sourced.
5. Expanding Beyond Core Cardiac Monitoring: Licensing pulse oximetry, accelerometry, and blood pressure technology from BioIntelliSense (August 2024, $15.0M upfront plus $40.0M in convertible notes) and early pilots in obstructive sleep apnea, heart failure, and hypertension signal an ambition to extend the ACM platform into adjacent chronic-disease monitoring.

---

2. Product Portfolio

iRhythm does not report separate operating segments; its business is best read through its monitoring product line and software platform.

---

3. Competitive Landscape

iRhythm names competitors across three distinct categories of rivalry.

Patch / Remote Monitoring Competitors

BioTelemetry (owned by Royal Philips), Preventice Solutions (owned by Boston Scientific), and Bardy Diagnostics (BardyDx, under Hill-Rom, now part of Baxter) compete directly in patch-based and remote cardiac monitoring. Each is backed by a much larger parent, giving them broader distribution than iRhythm, even as iRhythm claims superior diagnostic yield.

Legacy Holter Monitor Makers

GE Healthcare, Philips Healthcare, Spacelabs Healthcare, Welch Allyn, and Mortara Instrument (also under Hill-Rom/Baxter) represent the older, shorter-duration Holter monitor category that iRhythm's clinical studies (CAMELOT, AVALON) argue is less effective than its longer-wear patch approach.

Consumer Wearables

Apple and Fitbit have added non-continuous ECG and irregular-rhythm notification features to consumer smartwatches since 2021–2022 — a longer-term, indirect competitive threat that could redirect some lower-acuity monitoring demand away from clinical-grade services like Zio, even though consumer wearables are not full diagnostic replacements today.

       AMBULATORY CARDIAC MONITORING POSITIONING
  High  ┌────────────────────────────────────────────┐
        │  [BioTelemetry/Philips] [Preventice/Boston Scientific]
CLINICAL│        [iRhythm]            [BardyDx/Baxter]
 RIGOR  │
        │                                  [Apple/Fitbit]
  Low   └────────────────────────────────────────────┘
         Niche/startup entrants          Large diversified parents

iRhythm's position is that of the clinically-proven category leader competing against rivals backed by far larger parent companies on one side, and a slower-moving consumer-wearable threat on the other.

---

4. Strategic Strengths & Risks

Strengths

• Category Leadership: An estimated 70%+ share of U.S. LTCM services and ~40% of the core ACM market gives iRhythm meaningful scale advantages in data, clinical evidence, and payor relationships.
• Proprietary AI + Service Integration: The combination of FDA-cleared deep-learning algorithms with owned IDTFs and employed technicians is a workflow competitors backed by hardware-only strategies have struggled to match.
• Improving Profitability: Gross margin rose to 70.6% in 2025 from 68.9% in 2024, and the net loss narrowed to $44.6 million from $113.3 million, showing the service model's economics improving with scale.
• Platform Expansion Optionality: The BioIntelliSense license and early pilots in sleep apnea, heart failure, and hypertension give iRhythm a credible path to extend its monitoring platform beyond cardiac arrhythmia alone.

Risks

• Reimbursement Dependency: With CPT-code-based billing and roughly 83% of revenue from third-party payors (24% Medicare), any adverse coding or reimbursement rate change directly affects revenue.
• Larger, Better-Capitalized Rivals: BioTelemetry, Preventice, and Bardy Diagnostics are each backed by Philips, Boston Scientific, and Baxter respectively — companies with far greater financial and distribution resources than iRhythm.
• Consumer Wearable Encroachment: Continued improvement in Apple and Fitbit ECG features could gradually erode demand for professional monitoring in lower-acuity use cases, even if clinical-grade diagnosis remains differentiated for now.
• Single-Sourced Components: Key manufacturing inputs (ASICs, applicator seals, sensor polymers) remain single-sourced, creating supply-chain concentration risk at the Cypress, California facility.
• Continued Net Losses: Despite margin improvement, iRhythm posted a $44.6 million net loss in 2025, and 2026 guidance of an 11.5%-12.5% adjusted EBITDA margin shows profitability is still a work in progress at scale.
• Corporate Restructuring Transition Risk: The January 2026 holding company reorganization (iRhythm Holdings, Inc. becoming successor registrant) is a structural change that, while typically low-risk, still requires careful execution across contracts, regulatory registrations, and investor communications.

---

5. Financial Overview

---

6. Summary Conclusion

iRhythm's business model is built on selling a complete ambulatory cardiac monitoring service — not just a wearable patch — combining a proprietary AI-assisted analysis platform with owned diagnostic facilities and a reimbursement-driven billing model that has let it capture a dominant share of the U.S. long-term continuous monitoring market. Its moat rests on clinical evidence, scale, and an AI/service workflow that larger device-only competitors have not matched, even though those competitors' corporate parents (Philips, Boston Scientific, Baxter) have far deeper pockets.

The company's biggest forward risk is that its moat, while real, is not immune to two different pressures at once: reimbursement-dependent revenue that regulators and payors could reshape, and a slow-building but real threat from consumer wearables (Apple, Fitbit) that could eventually erode demand at the lower-acuity end of the market iRhythm has spent years building.